By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Neuraltus Pharmaceuticals, Inc. 

2483 E. Bayshore Road
Suite 212
Palo Alto  California  94303   U.S.A.
Phone: 650-424-1600 Fax: 650-320-8504



Company News
Neuraltus Pharmaceuticals, Inc.' ALS Treatment Candidate, NP001, Highlighted At ALS Research Group Summit 9/17/2014 8:41:55 AM
Neuraltus Pharmaceuticals, Inc.' NP001 Phase 2 Results Highlighted At The 24th International Symposium On ALS/MND 12/9/2013 7:48:47 AM
Neuraltus Pharmaceuticals, Inc. Seeks $30 Million for New Lou Gehrig's Disease Drug Trial 10/10/2013 7:36:59 AM
Neuraltus Pharmaceuticals, Inc. Names Richard L. Casey as President and Chief Executive Officer 10/8/2013 6:22:20 AM
Cannabis Science Inc. Appoints Michael McGrath, MD, PhD, Professor, Departments of Laboratory Medicine, Pathology, and Medicine, University of California, San Francisco (UCSF), and Co-Founder of Biotechs Pathologica LLC and Neuraltus Pharmaceuticals, Inc., to the Company's Scientific Advisory Board 3/28/2013 6:36:33 AM
Neuraltus Pharmaceuticals, Inc. Announces Phase 2 Clinical Results for NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) 10/30/2012 9:42:34 AM
Andrew Gengos Out, John Walker in as Neuraltus Pharmaceuticals, Inc. CEO 9/12/2012 8:27:01 AM
Drug Developer Neuraltus Pharmaceuticals, Inc. Raises $9.6 Million Toward $11 Million Goal 12/22/2011 7:36:49 AM
Neuraltus Pharmaceuticals, Inc. Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinson's Disease 12/3/2010 7:25:43 AM
Neuraltus Pharmaceuticals, Inc. Reports Clinical Results from Phase 1 NP001 Study in the Treatment of Amyotrophic Lateral Sclerosis (ALS) 11/30/2010 7:04:13 AM